|
US5852188A
(en)
|
1990-01-11 |
1998-12-22 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having chiral phosphorus linkages
|
|
DE59108644D1
(de)
|
1990-07-02 |
1997-05-07 |
Hoechst Ag |
Oligonucleotid-analoge mit terminalen 3'-3'-bzw. 5'-5'-Internucleotidverknüpfungen
|
|
US5512668A
(en)
|
1991-03-06 |
1996-04-30 |
Polish Academy Of Sciences |
Solid phase oligonucleotide synthesis using phospholane intermediates
|
|
TW323284B
(enExample)
|
1992-03-23 |
1997-12-21 |
Novartis Ag |
|
|
US5216168A
(en)
|
1992-04-01 |
1993-06-01 |
G. D. Searle & Co. |
2- and 3- amino and azido derivatives of 1,5-iminosugars
|
|
US6242589B1
(en)
|
1998-07-14 |
2001-06-05 |
Isis Pharmaceuticals, Inc. |
Phosphorothioate oligonucleotides having modified internucleoside linkages
|
|
US6617442B1
(en)
|
1999-09-30 |
2003-09-09 |
Isis Pharmaceuticals, Inc. |
Human Rnase H1 and oligonucleotide compositions thereof
|
|
US20030138797A1
(en)
|
2001-06-29 |
2003-07-24 |
Micrologix Biotech Inc. |
Nucleic acid-based compounds
|
|
WO2003025139A2
(en)
|
2001-09-17 |
2003-03-27 |
Mayo Foundation For Medical Education And Research |
Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
|
|
JP4348044B2
(ja)
|
2002-02-12 |
2009-10-21 |
株式会社キラルジェン |
立体規則性の高いジヌクレオシドホスホロチオエートの製造法
|
|
US8232383B2
(en)
|
2002-02-20 |
2012-07-31 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US8101348B2
(en)
|
2002-07-10 |
2012-01-24 |
Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. |
RNA-interference by single-stranded RNA molecules
|
|
AU2003261449A1
(en)
|
2002-08-07 |
2004-02-25 |
|
Compositions for rna interference and methods of use thereof
|
|
AR040996A1
(es)
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
Acidos nucleicos inmunoestimuladores
|
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
|
JP2005089441A
(ja)
|
2003-08-08 |
2005-04-07 |
Toudai Tlo Ltd |
立体規則性の高いリン原子修飾ヌクレオチド類縁体の製造法
|
|
JP4580870B2
(ja)
|
2003-09-02 |
2010-11-17 |
株式会社キラルジェン |
リボヌクレオチド又はリボヌクレオチド誘導体の製造方法
|
|
JP4616175B2
(ja)
|
2003-09-02 |
2011-01-19 |
株式会社キラルジェン |
５’−ホスフィチル化モノマーおよびｈ−ホスホネートオリゴヌクレオチド誘導体の製造方法
|
|
MY145571A
(en)
|
2003-12-19 |
2012-02-29 |
Ciba Holding Inc |
Fluorocarbon terminated oligo-and poly-carbonates as surface modifiers
|
|
WO2005070859A1
(ja)
|
2004-01-27 |
2005-08-04 |
Takeshi Wada |
フルオラス担体およびそれを用いたオリゴヌクレオチド誘導体の製造方法
|
|
WO2005085272A1
(ja)
|
2004-03-05 |
2005-09-15 |
Takeshi Wada |
ボラノホスフェートモノマーおよびそれを用いたオリゴヌクレオチド誘導体の製造方法
|
|
WO2005092909A1
(ja)
|
2004-03-25 |
2005-10-06 |
Toudai Tlo, Ltd. |
立体規則性の高いリボヌクレオチド類縁体及びデオキシリボヌクレオチド類縁体の製造法
|
|
EP2933332A1
(en)
|
2004-06-28 |
2015-10-21 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
|
US7427675B2
(en)
|
2004-08-23 |
2008-09-23 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for the characterization of oligonucleotides
|
|
DE502005008153D1
(de)
|
2005-11-23 |
2009-10-29 |
Roche Diagnostics Gmbh |
Polynukleotid mit Phosphatmimetikum
|
|
WO2008128686A1
(en)
|
2007-04-18 |
2008-10-30 |
Roche Diagnostics Gmbh |
Nucleotide with an alpha-phosphate mimetic
|
|
ES2639852T3
(es)
|
2007-10-26 |
2017-10-30 |
Academisch Ziekenhuis Leiden |
Medios y métodos para contrarrestar los trastornos musculares
|
|
US9290534B2
(en)
|
2008-04-04 |
2016-03-22 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside
|
|
CA2721333C
(en)
|
2008-04-15 |
2020-12-01 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for nucleic acid delivery
|
|
US8324366B2
(en)
|
2008-04-29 |
2012-12-04 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for delivering RNAI using lipoproteins
|
|
US20120059045A1
(en)
|
2008-10-24 |
2012-03-08 |
Isis Pharmaceuticals, Inc. |
Methods of using oligomeric compounds comprising 2'-substituted nucleosides
|
|
EP2447274B1
(en)
|
2008-10-24 |
2017-10-04 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
|
AU2009310557B2
(en)
|
2008-10-27 |
2014-09-11 |
Academisch Ziekenhuis Leiden |
Methods and means for efficient skipping of exon 45 in Duchenne Muscular Dystrophy pre-mRNA
|
|
CN102282155B
(zh)
|
2008-12-02 |
2017-06-09 |
日本波涛生命科学公司 |
磷原子修饰的核酸的合成方法
|
|
US9023820B2
(en)
|
2009-01-26 |
2015-05-05 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein C-III expression
|
|
RU2612521C2
(ru)
|
2009-07-06 |
2017-03-09 |
Онтории, Инк. |
Новые пролекарства нуклеиновых кислот и способы их применения
|
|
WO2011005860A2
(en)
|
2009-07-07 |
2011-01-13 |
Alnylam Pharmaceuticals, Inc. |
5' phosphate mimics
|
|
ES2586683T3
(es)
|
2009-09-16 |
2016-10-18 |
Wave Life Sciences Japan, Inc. |
Grupo protector novedoso para sintetizar ARN y derivados del mismo
|
|
WO2011109427A2
(en)
|
2010-03-01 |
2011-09-09 |
Alnylam Pharmaceuticals, Inc. |
Improving the biological activity of sirna through modulation of its thermodynamic profile
|
|
JP2011184318A
(ja)
|
2010-03-05 |
2011-09-22 |
Univ Of Tokyo |
リボヌクレシドｈ−ボラノホスホネート
|
|
JP5847700B2
(ja)
|
2010-03-05 |
2016-01-27 |
株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ |
リボヌクレオシドホスホロチオエートの製造方法
|
|
US20130156845A1
(en)
|
2010-04-29 |
2013-06-20 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
|
TWI541024B
(zh)
|
2010-09-01 |
2016-07-11 |
日本新藥股份有限公司 |
反義核酸
|
|
CA2812046A1
(en)
|
2010-09-15 |
2012-03-22 |
Alnylam Pharmaceuticals, Inc. |
Modified irna agents
|
|
JP5868324B2
(ja)
|
2010-09-24 |
2016-02-24 |
株式会社Wave Life Sciences Japan |
不斉補助基
|
|
JP6093924B2
(ja)
|
2010-11-30 |
2017-03-15 |
株式会社Wave Life Sciences Japan |
２’−ｏ−修飾ｒｎａ
|
|
SG194671A1
(en)
|
2011-04-27 |
2013-12-30 |
Isis Pharmaceuticals Inc |
Modulation of apolipoprotein ciii (apociii) expression
|
|
MX390699B
(es)
|
2011-06-21 |
2025-03-21 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibicion de genes para apolipoproteina c-iii (apoc3).
|
|
WO2013009735A1
(en)
|
2011-07-13 |
2013-01-17 |
Merck Sharp & Dohme Corp. |
5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
|
CN103796657B
(zh)
|
2011-07-19 |
2017-07-11 |
波涛生命科学有限公司 |
合成官能化核酸的方法
|
|
EP2792746A4
(en)
|
2011-12-12 |
2015-09-16 |
Nat Cerebral & Cardiovascular Ct |
OLIGONUCLEOTIDE AND THERAPEUTIC FOR HYPERLIPIDEMIA WITH THIS AS AN ACTIVE SUBSTANCE
|
|
NZ627896A
(en)
*
|
2012-01-27 |
2016-11-25 |
Biomarin Technologies B V |
Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
|
|
EP2870246B1
(en)
|
2012-07-03 |
2019-09-11 |
BioMarin Technologies B.V. |
Oligonucleotide for the treatment of muscular dystrophy patients
|
|
CA2879066C
(en)
|
2012-07-13 |
2019-08-13 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant
|
|
PL2872485T3
(pl)
|
2012-07-13 |
2021-05-31 |
Wave Life Sciences Ltd. |
Asymetryczna grupa pomocnicza
|
|
KR102213609B1
(ko)
|
2012-07-13 |
2021-02-08 |
웨이브 라이프 사이언시스 리미티드 |
키랄 제어
|
|
CN104837996A
(zh)
|
2012-11-15 |
2015-08-12 |
罗氏创新中心哥本哈根有限公司 |
抗apob反义缀合物化合物
|
|
DK2956176T3
(en)
|
2013-02-14 |
2018-08-27 |
Ionis Pharmaceuticals Inc |
MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS
|
|
DK2992098T3
(da)
|
2013-05-01 |
2019-06-17 |
Ionis Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
|
|
JPWO2015108047A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
|
|
US10322173B2
(en)
|
2014-01-15 |
2019-06-18 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
|
|
JPWO2015108048A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
|
BR112016016400A2
(pt)
|
2014-01-16 |
2017-10-03 |
Wave Life Sciences Ltd |
Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
|
|
DK3118311T3
(en)
|
2014-03-12 |
2019-03-11 |
Nippon Shinyaku Co Ltd |
Antisense nucleic acid
|
|
US9382540B2
(en)
|
2014-05-01 |
2016-07-05 |
Isis Pharmaceuticals, Inc |
Compositions and methods for modulating angiopoietin-like 3 expression
|
|
RU2708237C2
(ru)
*
|
2014-08-22 |
2019-12-05 |
Общество с ограниченной ответственностью "НооГен" |
Модифицированные олигонуклеотиды и способ их получения
|
|
JP2017535552A
(ja)
|
2014-11-17 |
2017-11-30 |
アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
アポリポタンパク質Ｃ３（ＡＰＯＣ３）ｉＲＮＡ組成物およびその使用方法
|
|
CA2976445A1
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
|
PL3277814T3
(pl)
|
2015-04-03 |
2020-11-30 |
University Of Massachusetts |
Związki oligonukleotydowe ukierunkowane na mrna huntingtyny
|
|
IL320434A
(en)
|
2015-07-22 |
2025-06-01 |
Wave Life Sciences Ltd |
Oligonucleotide preparations and methods
|
|
WO2017048620A1
(en)
|
2015-09-14 |
2017-03-23 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
|
|
IL295755A
(en)
|
2015-10-09 |
2022-10-01 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods thereof
|
|
EP3858993A1
(en)
|
2015-10-09 |
2021-08-04 |
Sarepta Therapeutics, Inc. |
Compositions and methods for treating duchenne muscular dystrophy and related disorders
|
|
US10478503B2
(en)
|
2016-01-31 |
2019-11-19 |
University Of Massachusetts |
Branched oligonucleotides
|
|
CN108779132B
(zh)
|
2016-03-13 |
2022-04-15 |
波涛生命科学有限公司 |
用于亚磷酰胺和寡核苷酸合成的组合物和方法
|
|
EP3452596A4
(en)
|
2016-05-04 |
2020-03-18 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS
|
|
CN109462995A
(zh)
|
2016-05-04 |
2019-03-12 |
波涛生命科学有限公司 |
生物活性剂的方法和组合物
|
|
CA3024456A1
(en)
|
2016-05-24 |
2017-11-30 |
Sarepta Therapeutics, Inc. |
Processes for preparing phosphorodiamidate morpholino oligomers
|
|
JP2019520339A
(ja)
|
2016-06-03 |
2019-07-18 |
ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
オリゴヌクレオチド、その組成物および方法
|
|
MX2018016253A
(es)
*
|
2016-07-05 |
2019-09-09 |
Biomarin Tech Bv |
Oligonucleotidos de conmutacion o modulacion de empalme de pre-arnm que comprenden radicales de andamio biciclicos, con caracteristicas mejoradas para el tratamiento de trastornos geneticos.
|
|
US20190330626A1
(en)
*
|
2016-07-15 |
2019-10-31 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for use in dystrophin transcript
|
|
WO2018022473A1
(en)
|
2016-07-25 |
2018-02-01 |
Wave Life Sciences Ltd. |
Phasing
|
|
RU2016138168A
(ru)
|
2016-09-26 |
2018-03-29 |
Оксфордский Университет |
Аналоги олигонуклеотидов как средства коррекции сплайсинга для лечения мышечной дистрофии дюшена
|
|
US11873316B2
(en)
|
2016-11-23 |
2024-01-16 |
Wave Life Sciences Ltd. |
Compositions and methods for phosphoramidite and oligonucleotide synthesis
|
|
RU2740501C2
(ru)
|
2017-02-21 |
2021-01-14 |
Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) |
МОДИФИЦИРОВАННЫЕ ОЛИГОНУКЛЕОТИДЫ, АКТИВИРУЮЩИЕ РНКазу Н
|
|
CN120330183A
(zh)
|
2017-06-02 |
2025-07-18 |
波涛生命科学有限公司 |
寡核苷酸组合物及其使用方法
|
|
JP2020522510A
(ja)
|
2017-06-02 |
2020-07-30 |
ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
オリゴヌクレオチド組成物及びその使用方法
|
|
CA3065523A1
(en)
|
2017-06-02 |
2018-12-06 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
US11718638B2
(en)
|
2017-06-21 |
2023-08-08 |
Wave Life Sciences Ltd. |
Compounds, compositions and methods for synthesis
|
|
WO2019002237A1
(en)
|
2017-06-28 |
2019-01-03 |
Roche Innovation Center Copenhagen A/S |
METHOD OF MULTIPLE COUPLING AND OXIDATION
|
|
EP3664816A4
(en)
|
2017-08-08 |
2021-05-19 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND RELATED PROCESSES
|
|
CA3072110A1
(en)
|
2017-09-18 |
2019-03-21 |
Wave Life Sciences Ltd. |
Technologies for oligonucleotide preparation
|
|
EP3691657A4
(en)
|
2017-10-04 |
2021-07-21 |
Avidity Biosciences, Inc. |
NUCLEIC ACID POLYPEPTIDE COMPOSITIONS AND USES THEREOF
|
|
EP3694530A4
(en)
|
2017-10-12 |
2021-06-30 |
Wave Life Sciences Ltd. |
COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
|
|
UY38003A
(es)
|
2017-12-12 |
2019-06-28 |
Amgen Inc |
Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas
|
|
SG11202009877XA
(en)
|
2018-04-12 |
2020-11-27 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods of use thereof
|
|
US12391942B2
(en)
|
2018-05-11 |
2025-08-19 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
TW202542311A
(zh)
|
2018-09-19 |
2025-11-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
|
JP2022513719A
(ja)
|
2018-12-06 |
2022-02-09 |
ウェイブ ライフ サイエンシズ リミテッド |
オリゴヌクレオチド組成物及びその方法
|
|
CN113423385A
(zh)
|
2019-02-01 |
2021-09-21 |
波涛生命科学有限公司 |
寡核苷酸组合物及其方法
|
|
JP2022525541A
(ja)
|
2019-03-20 |
2022-05-17 |
ウェイブ ライフ サイエンシズ リミテッド |
オリゴヌクレオチド調製に有用な技術
|
|
WO2020196662A1
(ja)
|
2019-03-25 |
2020-10-01 |
国立大学法人東京医科歯科大学 |
二本鎖核酸複合体及びその使用
|
|
BR112021021203A2
(pt)
|
2019-04-25 |
2022-01-04 |
Wave Life Sciences Ltd |
Oligonucleotídeo; composição de oligonucleotídeo quiralmente controlada; composição farmacêutica; método para prevenir, tratar ou melhorar uma afecção, distúrbio ou doença relacionada a ush2a e/ou prevenir, atrasar o início, desenvolvimento e/ou progresso, e/ou tratar uma afecção, distúrbio ou doença relacionada a ush2a em um indivíduo suscetível à mesma ou que sofre da mesma; método para aumentar o nível de salto de um éxon prejudicial em uma transcrição de gene ush2a ou seu produto de gene em uma célula; método para prevenir, atrasar o início ou progressão de, tratar ou melhorar uma afecção, distúrbio ou doença relacionada a ush2a em um indivíduo suscetível à mesma ou que sofre da mesma; método para saltar um éxon prejudicial 13 em um alelo de ush2a em um indivíduo; método para produzir ou aumentar o nível de um éxon de proteína ush2a com salto 13 em um sistema; e composto, oligonucleotídeo, composição ou método
|
|
SG11202111387YA
(en)
|
2019-04-25 |
2021-11-29 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods of use thereof
|
|
EP3965780A4
(en)
|
2019-05-09 |
2023-10-25 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE
|
|
JP7766589B2
(ja)
|
2019-10-06 |
2025-11-10 |
ウェイブ ライフ サイエンシズ リミテッド |
オリゴヌクレオチド組成物及びその使用方法
|
|
JP2022550915A
(ja)
|
2019-10-06 |
2022-12-05 |
ウェイブ ライフ サイエンシズ リミテッド |
オリゴヌクレオチド組成物及びその使用方法
|
|
WO2021126734A1
(en)
|
2019-12-16 |
2021-06-24 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
|
JP2023515862A
(ja)
|
2020-03-01 |
2023-04-14 |
ウェイブ ライフ サイエンシズ リミテッド |
オリゴヌクレオチド組成物及びその方法
|
|
AR121672A1
(es)
|
2020-03-26 |
2022-06-29 |
Arrowhead Pharmaceuticals Inc |
AGENTES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3, COMPOSICIONES FARMACÉUTICAS DE ESTA, Y MÉTODOS DE USO
|
|
AU2021277407A1
(en)
|
2020-05-22 |
2022-11-17 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
|
MX2022014606A
(es)
|
2020-05-22 |
2023-03-08 |
Wave Life Sciences Ltd |
Composiciones de oligonucleótidos bicatenarios y métodos relacionados con las mismas.
|
|
WO2022046723A1
(en)
|
2020-08-24 |
2022-03-03 |
Wave Life Sciences Ltd. |
Immunoassays for detecting wild type huntingtin protein and methods of treatment employing such immunoassays
|
|
WO2022046667A1
(en)
|
2020-08-24 |
2022-03-03 |
Wave Life Sciences Ltd. |
Cells and non-human animals engineered to express adar1 and uses thereof
|
|
WO2022067023A1
(en)
|
2020-09-24 |
2022-03-31 |
Mayo Foundation For Medical Education And Research |
Screening platforms
|
|
US20240033280A1
(en)
|
2020-10-02 |
2024-02-01 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing apociii expression
|
|
KR20230118716A
(ko)
|
2020-11-08 |
2023-08-11 |
웨이브 라이프 사이언시스 리미티드 |
올리고뉴클레오티드 조성물 및 이의 방법
|
|
CN116507724A
(zh)
|
2020-11-08 |
2023-07-28 |
波涛生命科学有限公司 |
寡核苷酸组合物及其方法
|
|
EP4396354A4
(en)
|
2021-09-26 |
2025-12-03 |
Wave Life Sciences Ltd |
OLIGONUCLEOTIDE COMPOSITIONS AND ASSOCIATED PROCESSES
|
|
EP4404942A2
(en)
|
2021-09-26 |
2024-07-31 |
Wave Life Sciences Ltd. |
Compositions for editing mecp2 transcripts and methods thereof
|
|
CA3236136A1
(en)
|
2021-10-27 |
2023-05-04 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
EP4422645A4
(en)
|
2021-10-27 |
2025-12-03 |
Wave Life Sciences Ltd |
OLIGONUCLEOTID COMPOSITIONS AND THEIR METHODS OF USE
|
|
EP4476202A1
(en)
|
2022-02-11 |
2024-12-18 |
Wave Life Sciences Ltd. |
Stereoselective technologies for chiral compounds
|
|
AU2023227808A1
(en)
|
2022-03-02 |
2024-09-19 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof for exon skipping
|
|
EP4507700A2
(en)
|
2022-04-15 |
2025-02-19 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods relating thereto
|
|
US20250302995A1
(en)
|
2022-05-12 |
2025-10-02 |
Chikdu Shakti Shivalila |
Oligonucleotide compositions and methods thereof
|
|
AU2023321711A1
(en)
|
2022-08-11 |
2025-02-20 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
|
WO2025030155A1
(en)
|
2023-08-03 |
2025-02-06 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|